Search
for
Sort by
Research 61–90 of 1000+
- The Non-Cosmetic Dermatological Use of Botulinum Neurotoxin
- SUN-005 Hirsutism Due to Bilateral Leydig Cell Tumors
- SAT-LB2 Elevated Testosterone Secondary to Leydig Cell Hyperplasia in Bilateral Ovaries
- 5 Diverse Skin Type Considerations and Applications for Nonsurgical Combinations
- Das Cushing-Syndrom im Spiegel der Haut
- Book Reviews
- 원저 : 원형탈모증에 대한 스테로이드제 미니 펄스요법의 효과
- 원저 : Mohs 미세도식 수술을 이용한 안검부 기저세포암의 준임상적 침윤 유형에 관한 연구
- 133 TIME LAGS BETWEEN VARIOUS MATURITY MEASURES AND SPERMACRCHE
- The safety of 52 weeks of oral DHEA therapy for postmenopausal women
- Some Clues and Pitfalls in the Diagnosis of Acromegaly
- [Cutaneous effects in hormonal contraception].
- (13) Tolerance of spironolactone
- AN OVERVIEW OF AMENORRHEA
- A Comprehensive Review of Acne Vulgaris
- Acne: Transient Arrest in the Homeostatic Host–Microbiota Dialog?
- Acne exacerbation after tofacitinib treatment for alopecia areata
- Generative adversarial networks for anonymous acneic face dataset generation
- Acne exacerbation after tofacitinib treatment for alopecia areata
- Beyond Acne: Unmasking a Varioliform Scar in an Adolescent Boy
- Oral Isotretinoin in HIV-Positive Women with Acne: Report of Three Cases
- Treatment of acne scars by fractional bipolar radiofrequency energy
- Referee report. For: Comparison between Tazarotene 0.05% gel and Adapelene 0.1% gel in acne patients [version 1; peer review: 1 approved with reservations]
- Correction of age-related changes of the face skin using radiofrequency micro needling. Brief literature review
- Case 1: Severe acne – not just skin deep
- Management of Hirsutism Associated With Obese PCOD - A Case Report
- Isotretinoin for the treatment of facial lichen planopilaris: A new indication for an old drug, a case series study
- Clinical Outcomes and Patient Satisfaction of Platelet-Rich Plasma Injections in Regenerative Aesthetic Medicine
- Facial Papules in a Patient With Lichen Planopilaris
- Acne Resolution Rates: Results of a Single-Blind, Randomized, Controlled, Parallel Phase III Trial with EE/CMA (Belara<sup>®</sup>) and EE/LNG (Microgynon<sup>®</sup>)